BR112016029624A2 - terapia usando um inibidor do fator xii em um distúrbio neurotraumático - Google Patents
terapia usando um inibidor do fator xii em um distúrbio neurotraumáticoInfo
- Publication number
- BR112016029624A2 BR112016029624A2 BR112016029624A BR112016029624A BR112016029624A2 BR 112016029624 A2 BR112016029624 A2 BR 112016029624A2 BR 112016029624 A BR112016029624 A BR 112016029624A BR 112016029624 A BR112016029624 A BR 112016029624A BR 112016029624 A2 BR112016029624 A2 BR 112016029624A2
- Authority
- BR
- Brazil
- Prior art keywords
- factor xii
- therapy
- xii inhibitor
- neurotraumatic disorder
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Abstract
a presente invenção refere-se ao uso de um inibidor do fator xii (fxii) no tratamento de um distúrbio traumático resultante de uma lesão traumática do cérebro (traumatismo cranioencefálico, tbi) ou da medula espinhal (lesão medular, sci).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14172910 | 2014-06-18 | ||
PCT/EP2015/063760 WO2015193457A1 (en) | 2014-06-18 | 2015-06-18 | Therapy using a factor xii inhibitor in a neurotraumatic disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016029624A2 true BR112016029624A2 (pt) | 2017-10-24 |
Family
ID=50972542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016029624A BR112016029624A2 (pt) | 2014-06-18 | 2015-06-18 | terapia usando um inibidor do fator xii em um distúrbio neurotraumático |
Country Status (12)
Country | Link |
---|---|
US (2) | US20170114119A1 (pt) |
EP (1) | EP3157548B1 (pt) |
JP (1) | JP7109160B2 (pt) |
KR (1) | KR102513050B1 (pt) |
CN (1) | CN106456778A (pt) |
AU (1) | AU2015276089B2 (pt) |
BR (1) | BR112016029624A2 (pt) |
CA (1) | CA2950988C (pt) |
DK (1) | DK3157548T3 (pt) |
ES (1) | ES2886859T3 (pt) |
PL (1) | PL3157548T3 (pt) |
WO (1) | WO2015193457A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018069868A2 (pt) * | 2016-03-30 | 2019-01-29 | Sinntaxis AB | modulador alostérico negativo do receptor metabotrópico de glutamato 5, usos de um nam, e método de tratamento ou atenuação de dano cerebral maduro |
CA3019851A1 (en) * | 2016-04-06 | 2017-10-12 | Csl Limited | Method of treating atherosclerosis |
BR112020011240A2 (pt) | 2017-12-15 | 2020-11-24 | Csl Limited | uso de um inibidor de fxiia no tratamento de fibrose renal e/ou doença renal crônica |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
GB8901859D0 (en) | 1989-01-27 | 1989-03-15 | Shield Diagnostics Limited | Diagnostic test |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
CA2082643A1 (en) | 1990-05-10 | 1991-11-11 | Jan H. Nuijens | Inhibitors of factor xii activation and applications thereof |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
EP0575545B1 (en) | 1991-03-15 | 2003-05-21 | Amgen Inc. | Pegylation of polypeptides |
WO1996018412A1 (en) | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
CA2405912A1 (en) | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1572936A2 (en) | 2002-03-05 | 2005-09-14 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
ATE497783T1 (de) | 2003-05-06 | 2011-02-15 | Syntonix Pharmaceuticals Inc | Gerinnungsfaktor vii-fc chimäre proteine zur behandlung von hämostatischen krankheiten |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
AU2004251145C1 (en) | 2003-06-12 | 2011-04-14 | Eli Lilly And Company | GLP-1 analog fusion proteins |
US7550263B2 (en) | 2003-09-05 | 2009-06-23 | Gtc Biotherapeutics, Inc. | Method for the production of fusion proteins in transgenic mammal milk |
KR20060124656A (ko) | 2003-12-31 | 2006-12-05 | 메르크 파텐트 게엠베하 | 개선된 약물동태를 가지는 Fc-에리스로포이에틴 융합단백질 |
DK1830924T3 (da) * | 2004-12-23 | 2013-05-21 | Csl Behring Gmbh | Forebyggelse af thrombedannelse og/eller -stabilisering |
US8283319B2 (en) | 2007-02-12 | 2012-10-09 | Csl Behring Gmbh | Therapeutic application of Kazal-type serine protease inhibitors |
WO2011069090A1 (en) * | 2009-12-04 | 2011-06-09 | Alavita Pharmaceuticals, Inc. | Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine |
CN103501822A (zh) | 2010-12-17 | 2014-01-08 | 人类起源公司 | 使用胎盘干细胞治疗脊髓损伤和外伤性脑损伤 |
EP2497489A1 (en) * | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
EP2548892A1 (en) | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
KR102042982B1 (ko) | 2011-07-22 | 2019-11-11 | 체에스엘 베링 게엠베하 | 억제성 항-xii/xiia 인자 모노클로날 항체 및 이들의 사용 |
EP2623110A1 (en) * | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
EP2964255B1 (en) | 2013-03-08 | 2020-11-04 | CSL Behring GmbH | Treatment and prevention of remote ischemia-reperfusion injury |
US20160166660A1 (en) * | 2013-06-28 | 2016-06-16 | Csl Behring Gmbh | Combination therapy using a factor xii inhibitor and a c-1 inhibitor |
-
2015
- 2015-06-18 KR KR1020177001620A patent/KR102513050B1/ko active IP Right Grant
- 2015-06-18 EP EP15741128.1A patent/EP3157548B1/en active Active
- 2015-06-18 US US15/318,550 patent/US20170114119A1/en not_active Abandoned
- 2015-06-18 CA CA2950988A patent/CA2950988C/en active Active
- 2015-06-18 BR BR112016029624A patent/BR112016029624A2/pt active Search and Examination
- 2015-06-18 PL PL15741128T patent/PL3157548T3/pl unknown
- 2015-06-18 WO PCT/EP2015/063760 patent/WO2015193457A1/en active Application Filing
- 2015-06-18 ES ES15741128T patent/ES2886859T3/es active Active
- 2015-06-18 JP JP2016573808A patent/JP7109160B2/ja active Active
- 2015-06-18 CN CN201580032338.8A patent/CN106456778A/zh active Pending
- 2015-06-18 AU AU2015276089A patent/AU2015276089B2/en active Active
- 2015-06-18 DK DK15741128.1T patent/DK3157548T3/da active
-
2019
- 2019-10-29 US US16/666,886 patent/US20200131248A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
DK3157548T3 (da) | 2021-09-06 |
ES2886859T3 (es) | 2021-12-21 |
AU2015276089B2 (en) | 2021-03-18 |
EP3157548A1 (en) | 2017-04-26 |
EP3157548B1 (en) | 2021-08-04 |
JP2017524675A (ja) | 2017-08-31 |
AU2015276089A1 (en) | 2017-02-02 |
JP7109160B2 (ja) | 2022-07-29 |
PL3157548T3 (pl) | 2022-01-17 |
US20200131248A1 (en) | 2020-04-30 |
WO2015193457A1 (en) | 2015-12-23 |
US20170114119A1 (en) | 2017-04-27 |
CN106456778A (zh) | 2017-02-22 |
CA2950988C (en) | 2024-02-06 |
KR20170016503A (ko) | 2017-02-13 |
CA2950988A1 (en) | 2015-12-23 |
KR102513050B1 (ko) | 2023-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022001755A (es) | Compuestos de dinucleotidos ciclicos y metodos de uso. | |
MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
BR112017002332A2 (pt) | terapia de combinação para o tratamento de um paramixovírus | |
MX2017005834A (es) | Polinucleotidos aad para el tratamiento de la enfermedad de parkinson. | |
EP3263053A4 (en) | Medical treatment instrument | |
UY36068A (es) | INHIBIDORES DE TGF-ß Y MÉTODOS DE USO | |
EA201691594A1 (ru) | Циклопропиламины в качестве ингибиторов lsd1 | |
CO6791571A2 (es) | Moduladores de la proteína tirosina quinasa 7 (ptk7) para el tratamiento diagnóstico o profilaxis de trastornos neoplásicos | |
SG10201806849WA (en) | Cyclopropylamines as lsd1 inhibitors | |
WO2014176128A3 (en) | Compositions and methods for the therapy and diagnosis of influenza | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
MX2017004838A (es) | Composiciones de interleucina-15 y usos de estas. | |
EP3351188A4 (en) | ENDOSCOPE TREATMENT INSTRUMENT | |
BR112016028891A2 (pt) | processos de trens de sementes e usos dos mesmos | |
EP3351186A4 (en) | ENDOSCOPIC TREATMENT INSTRUMENT | |
DK3484502T3 (da) | Blodplasmafraktioner til behandling mod aldersrelaterede kognitive forstyrrelser | |
EP3351187A4 (en) | ENDOSCOPE TREATMENT INSTRUMENT | |
EP3351189A4 (en) | ENDOSCOPE TREATMENT INSTRUMENT | |
BR112018000776A2 (pt) | métodos para tratamento de câncer usando apilimod | |
IL255185A0 (en) | 1-Heteroaryl-indoline-4-carboxamides as gpr52 modulators for treatment or prevention of related disorders | |
UA118610C2 (uk) | Спіроциклічні інгібітори катепсину c | |
EP3134423A4 (en) | 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer | |
BR112018012313A2 (pt) | composições que compreendem 15-hepe e métodos para uso das mesmas | |
GB2549278B (en) | Use of cannabidivarin in the treatment of autism spectrum disorder | |
BR112019005539A2 (pt) | métodos de tratamento de lesão renal aguda |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |